Saltar al contenido
Merck

21685

Sigma-Aldrich

ATX Tris buffer

ready-to-use solution

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Beilstein:
3535773
Número MDL:
Código UNSPSC:
12161700
ID de la sustancia en PubChem:
NACRES:
NA.25

cadena SMILES

NC(CO)(CO)CO

InChI

1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2

Clave InChI

LENZDBCJOHFCAS-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Envase

6 bottles for the preparation of 1 L ready-to-use solution (each)

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Seong H Chow et al.
Journal of leukocyte biology, 108(3), 967-981 (2020-06-13)
Staphylococcus aureus causes necrotizing pneumonia by secreting toxins such as leukocidins that target front-line immune cells. The mechanism by which leukocidins kill innate immune cells and trigger inflammation during S. aureus lung infection, however, remains unresolved. Here, we explored human-induced
Timothy J Kidd et al.
Journal of clinical microbiology, 47(5), 1503-1509 (2009-03-06)
Pseudomonas aeruginosa is an important cause of pulmonary infection in cystic fibrosis (CF). Its correct identification ensures effective patient management and infection control strategies. However, little is known about how often CF sputum isolates are falsely identified as P. aeruginosa.
Sean Ekins et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(12), 2302-2308 (2010-09-17)
Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predictive in vivo, in vitro, and in silico models to identify compounds
Nigel Greene et al.
Chemical research in toxicology, 23(7), 1215-1222 (2010-06-18)
Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential
Zhichao Liu et al.
PLoS computational biology, 7(12), e1002310-e1002310 (2011-12-24)
Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be translated

Questions

  1. What is the concentration of Tris in a ready-to-use ATX-tris buffer (cat no 21685 Fluka)?

    1 answer
    1. The concentration of Tris buffer is considered proprietary.

      Helpful?

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico